Heavy Menstrual Bleeding: Hormonal and Nonhormonal Treatment
Core concept: Heavy menstrual bleeding requires assessment for pregnancy, hemodynamic compromise, anemia, structural disease, and possible endometrial pathology before selecting medical treatment.
Key clinical distinction: Nonhormonal agents, hormonal suppression, and urgent stabilization have different roles; the patient’s contraception and future fertility goals determine the best long-term pathway.
Prescribing priority: Separate acute severe bleeding from stable chronic disease, then match treatment to contraindications and desired outcomes (Cieri-Hutcherson, 2026).
Assess severity and causes
Ask about pad or tampon saturation, clots, bleeding duration, flooding, functional impairment, pregnancy possibility, medications (including anticoagulants), personal or family bleeding disorders, and symptoms of anemia. Check vital signs and blood loss severity; pregnancy testing and CBC/ferritin are frequently relevant. Determine whether pelvic examination, ultrasonography, or endometrial sampling is needed because of age, bleeding pattern, persistence, or risk factors. Hypotension, syncope, major hemorrhage, or severe anemia requires urgent stabilization rather than an outpatient chronic-bleeding prescription (Cieri-Hutcherson, 2026).
Options for stable chronic heavy bleeding
A 52-mg levonorgestrel IUD may substantially reduce blood loss and provide contraception, but FDA-labeled HMB treatment is device-specific. Mirena is labeled for HMB through five years and for contraception through eight years; replace by the end of year five if continued labeled HMB treatment is needed. Do not assume all 52-mg LNG-IUD products carry the same HMB indication. Eligible combined hormonal contraceptives and progestins may improve bleeding, while NSAIDs during menses can reduce blood loss and pain but may be inappropriate with renal, GI, bleeding, or cardiovascular risks (Bayer HealthCare Pharmaceuticals, 2025; Cieri-Hutcherson, 2026).
Tranexamic acid
Oral tranexamic acid is a nonhormonal antifibrinolytic for cyclic heavy menstrual bleeding, not contraception. The FDA-labeled dose with normal renal function is 1,300 mg orally three times daily for no more than five days during each menstrual period. The U.S. oral-tablet label adjusts by serum creatinine: greater than 1.4 to 2.8 mg/dL, 1,300 mg twice daily; greater than 2.8 to 5.7 mg/dL, 1,300 mg once daily; greater than 5.7 mg/dL, 650 mg once daily (each for a maximum of five days). Use serum-creatinine thresholds from the relevant product label rather than casually substituting an eGFR cut-off. Combined hormonal contraception, active or previous thromboembolic disease, and certain intrinsic thrombosis risks are contraindications. Evaluate endometrial pathology when indicated, and counsel about visual changes and thrombotic symptoms; do not confuse cyclic oral therapy with management of unstable acute bleeding (American Health Packaging, 2022; Cieri-Hutcherson, 2026).
Acute abnormal bleeding
For acute heavy bleeding in a stable patient, options include higher-dose oral progestin and combined hormonal regimens, with therapy chosen according to severity and contraindications. Management of unstable bleeding, possible pregnancy, suspected structural pathology, or a bleeding disorder is different and may require emergency assessment, procedural care, and transfusion planning. Do not confuse the treatment for acute cessation with the maintenance regimen intended to prevent recurrence (Cieri-Hutcherson, 2026).
Follow-up and therapy selection
Evaluate hemoglobin and iron deficiency, symptom control, quality of life, breakthrough bleeding, side effects, and treatment preference. Consider iron replacement when deficiency is present. Revisit diagnosis if bleeding persists despite adequate therapy rather than repeatedly escalating medication. Offer procedural evaluation when a structural cause or persistent treatment failure warrants it (Cieri-Hutcherson, 2026).
Quantify bleeding and correct the consequence, not only the symptom
Assess pregnancy risk, hemodynamic stability, anemia and iron deficiency, structural/endometrial risks, and reproductive goals before choosing treatment. Record baseline bleeding burden and CBC/ferritin, and correct iron deficiency. For a patient who also desires contraception, Mirena (52 mg LNG) has an FDA-labeled HMB indication through five years, distinct from its eight-year contraceptive indication. Tranexamic acid 1,300 mg orally three times daily for up to five days during menses is an option for eligible nonpregnant patients with regular heavy bleeding, but U.S. labeling contraindicates concurrent combined hormonal contraception. Reassess bleeding, Hb/ferritin, and adverse effects after treatment (Bayer HealthCare Pharmaceuticals, 2025; Cieri-Hutcherson, 2026).
Acute heavy bleeding changes the location of care
Hemodynamic compromise, syncope, rapid hemoglobin decline, pregnancy-related bleeding, or severe symptomatic anemia requires urgent evaluation and resuscitation rather than outpatient escalation of routine chronic-bleeding medication. Persistent bleeding despite treatment requires reconsideration of structural pathology, endometrial assessment when indicated, adherence, and whether the chosen regimen matches the patient’s reproductive goals. Recheck clinical bleeding and iron indices after an adequate trial (Cieri-Hutcherson, 2026).
Choose by reproductive goal and bleeding severity
| Scenario | Representative choice | Contraindications or limitations | Treatment endpoint |
|---|---|---|---|
| Chronic HMB + contraception desired | Mirena (52-mg LNG-IUD): HMB label through 5 years; contraception through 8 years | Check pregnancy, insertion eligibility, cavity distortion, and product-specific HMB labeling | Bleeding days and ferritin/Hb |
| Cyclic HMB + fertility desired | Tranexamic acid 1,300 mg PO TID, up to 5 d during menses | Contraindicated with CHCs; screen thrombosis risks and renal function | Menstrual volume and anemia |
| HMB + need cycle control | Eligible CHC/progestin pathway | Estrogen contraindications; adherence | Bleeding pattern and symptoms |
| Unstable acute heavy bleeding | Urgent stabilization and etiologic assessment | Outpatient oral schedule alone inadequate | Vitals, hemorrhage control, Hb |
Clinical application
A 36-year-old with regular heavy periods, ferritin 8 ng/mL, no identified structural lesion, and a desire for contraception compares Mirena (52-mg LNG-IUD) with monthly oral tranexamic acid. Mirena addresses contraception and HMB and is FDA-labeled for HMB treatment through five years, although its contraceptive indication extends to eight years. Tranexamic acid reduces menstrual bleeding but does not prevent pregnancy, and thrombotic risk and concurrent hormonal contraception must be assessed. Include iron replacement, follow-up CBC/ferritin and symptom measures. If immediate conception becomes the goal, favor an eligible noncontraceptive strategy; tachycardia with severe bleeding would prompt urgent evaluation (Bayer HealthCare Pharmaceuticals, 2025; Cieri-Hutcherson, 2026).
High-yield distinctions
Tranexamic acid is not contraception. LNG-IUD and oral hormonal methods are not equivalent in bleeding control or duration. Anemia and endometrial pathology must not be overlooked while treating symptoms.
Related YourDNP Resources
Pharmacology learning hub · Dysmenorrhea · Combined hormonal contraception · Amenorrhea and anovulatory bleeding
Content last reviewed:
References
American Health Packaging. (2022, June). Tranexamic acid tablets [Prescribing information]. DailyMed. https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cbc6f5b3-927e-4a94-8836-dbcd47ef97a8&type=display
Bayer HealthCare Pharmaceuticals Inc. (2025). Mirena (levonorgestrel-releasing intrauterine system) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dcbd6aa2-b3fa-479a-a676-56ea742962fc&type=display
Cieri-Hutcherson, N. E. (2026). Menstruation-related disorders and menopause. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 50). McGraw Hill.
Vernon, V. P. (2026). Contraception. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 49). McGraw Hill.